Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

BACKGROUND: Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase II IMvigor210 study demonstrated the efficacy and safety of atezolizumab, a programmed death-ligand 1-directed antibody, in patien...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Oncol
Hlavní autoři: Necchi, A, Joseph, R W, Loriot, Y, Hoffman-Censits, J, Perez-Gracia, J L, Petrylak, D P, Derleth, C L, Tayama, D, Zhu, Q, Ding, B, Kaiser, C, Rosenberg, J E
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834063/
https://ncbi.nlm.nih.gov/pubmed/28950298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx518
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky